MannKind Corporation
30930 Russell Ranch Road
Suite 301
Westlake Village
California
91362
United States
Website: http://www.mannkindcorp.com/
381 articles about MannKind Corporation
-
MannKind Corporation to Participate in the BTIG Biotechnology Conference
8/1/2022
MannKind Corporation, a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven Binder will participate in the BTIG Biotechnology Conference taking place on Monday, August 8 – Tuesday, August 9, 2022.
-
Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7
6/3/2022
MannKind Corporation will showcase its mealtime insulin solutions and expanding efforts within the diabetes community at the American Diabetes Association’s 82nd Scientific Sessions, June 3-7 in New Orleans.
-
Tyvaso DPI marks the first approval of a dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
-
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
5/24/2022
MannKind Corporation celebrated that the U.S. Food and Drug Administration has approved United Therapeutics’ Tyvaso DPI™ inhalation powder for the treatment of patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
-
Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device
5/17/2022
Zealand Pharma Announces Asset Purchase Agreement withMannKind Corporation forV-Go®Insulin Delivery Device
-
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
5/17/2022
MannKind Corporation announced that it has entered into an agreement with Zealand Pharma A/S to acquire V-Go® for $10 million, with additional sales-based milestones plus the cost of certain inventory.
-
MannKind Corporation Participating at Upcoming Conferences - May 09, 2022
5/9/2022
MannKind Corporation announced that it will be participating at upcoming conferences.
-
MannKind Corporation Reports 2022 First Quarter Financial Results
5/5/2022
MannKind Corporation reported financial results for the quarter ended March 31, 2022.
-
MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022
4/28/2022
MannKind Corporation will release its 2022 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM on Thursday, May 5, 2022.
-
MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30
4/27/2022
MannKind Corporation announced that it has presented a poster [Abstract #445] at the 15th International Conference on Advanced Technologies & Treatments for Diabetes held April 27-30 in Barcelona and virtually.
-
MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference
3/28/2022
MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.
-
MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit
3/22/2022
MannKind Corporation announced that its Chief Scientific Officer, Thomas Hofmann, MD, PhD, will participate in the Cantor Virtual Rare Orphan Disease Summit on Tuesday, March 29, 2022 at 8:00 am.
-
MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference
3/8/2022
MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a virtual presentation at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 4:00 pm.
-
Update on Tyvaso DPI™ New Drug Application
2/24/2022
MannKind Corporation was informed that the U.S. Food and Drug Administration issued an information request to United Therapeutics Corporation earlier this month regarding the New Drug Application for Tyvaso DPI, requesting additional information regarding the pulmonary safety of Tyvaso DPI related to a pending Citizen Petition.
-
MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results
2/24/2022
MannKind Corporation reported financial results for the fourth quarter and full year ended December 31, 2021.
-
MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022
2/21/2022
MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its management will host a conference call to discuss the financial results and corporate updates at 5:00 p.m. (Eastern Time) on Thursday, February 24, 2022.
-
MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference
2/10/2022
MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 pm.
-
It's been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.
-
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
1/5/2022
MannKind Corporation announced that has extended its collaboration with Thirona Bio, Inc. with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.
-
MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference
1/5/2022
MannKind Corporation announced that its Chief Executive Officer Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.